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  1Abstract  
  Advances in our understanding of the protozoan parasite Leishmania have been 
facilitated by the development of molecular and genetic tools.  One powerful approach for gene 
identification and analysis is transposon mutagenesis.  This can be performed directly in vivo, but 
often it is more convenient to generate transpositions in vitro for subsequent analysis in vivo, in a 
process termed ‘shuttle mutagenesis’.  The Drosophila element mariner is well-suited for 
application by either route.  Minimal mariner elements containing cis-acting elements required 
for transposition have been generated, which can be further modified to suit the needs of the 
experimenter.  Additional genetic markers and/or reporters can be introduced which are useful 
for procedures such as insertional mutagenesis, shotgun sequencing, or the generation of protein 
and transcriptional fusions for subsequent analysis.  Active transposase can readily be generated 
following expression in E. coli, and efficiencies of 10
-3/target can be obtained, allowing the 
generation of large transposon insertion libraries suitable for subsequent screening in vivo.  In 
this article, we will explain the steps necessary to purify active Mos1 transposase and conduct an 
in vitro transposition reaction.  We will also discuss some of the considerations relevant to the 
design and application of functional mariner-elements (donor plasmids) relevant to studies in 
Leishmania and other organisms. 
 
1.  Introduction 
Protozoan parasites like Leishmania are responsible for a number of illnesses that cause 
significant mortality and morbidity throughout the world (1).  Genetic and genomic tools now 
available for the study of the parasite promise to greatly increase our understanding of how this 
  2parasite survives and causes disease, and ultimately lead to improved methods for overcoming 
this disease by immunization or chemotherapy (2-5).   
Two common tasks in parasite genetics are first the identification of genes mediating 
interesting functions, and secondly dissection of the role, regulation and localization of encoded 
proteins.  A powerful tool suitable for this task in many organisms is transposon-based 
mutagenesis (6).  This can be performed directly in vivo, where both the transposon and active 
transposase are introduced or expressed in the parasite, or in vitro, where transposition is 
performed in vitro and the products introduced into the parasite for subsequent analysis (Fig. 1). 
In vivo strategies are especially powerful when incorporated into forward genetic approaches, as 
mutants generated are simultaneously tagged by the transposon, which can then be used to 
recover the affected gene.  Unfortunately, Leishmania is an asexual diploid in the laboratory, and 
for most loci recovery of loss of function mutations requires at least two genetic events (7).  
However this approach is widely used in haploid organisms, or ones in which homozygosity can 
be readily attained in some manner (for example by sexual crossing). 
In vivo transposition systems can be challenging to set up, due to the constraints inherent 
in engineering transposase expression and controlling transposition.  For many purposes, in vitro 
transposition is more convenient and as powerful.  In a process termed shuttle mutagenesis, 
transfectable molecular constructs (for example, Leishmania DNA cloned in the shuttle E. coli-
Leishmania vector cLHYG; 8) are subjected to transposition in vitro, and then the population of 
independent insertions scored for phenotypes following transfection back into Leishmania (Fig. 
1).  The transposon insertion library also can be used for rapid and systematic DNA sequencing 
if necessary, using primers situated within the transposon.  We have found this approach 
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genetic screens in Leishmania. 
Beyond their role as insertional mutagens, transposons can be engineered to contain 
reporters such as the green fluorescent protein (GFP), β-galactosidase, β-glucosidase or β-
lactamase, or selectable markers such as NEO, HYG or PHLEO, which mediate resistance to 
G418/geneticin, hygromycin B or phleomycin/zeocin, respectively.  Following transposition, 
activation of the reporter or marker can then be used to identify and/or select for transcribed or 
translated regions of the genome, a procedure commonly referred to as gene/protein ‘trapping’.  
By studying expression and/or localization of the reporter proteins, one can then conveniently 
(albeit indirectly) monitor gene expression and protein localization (9, 10).   
Several transposon systems have been engineered to the point that they are readily 
incorporated into shuttle transposon mutagenesis strategies; these include Tn7 (11), Tn5 (12), 
Ty1 (13), Mu (14) and several Tc1/mariner family elements (15-17).  Relevant factors include 
the availability, cost and/or ease of purification of transposase, the randomness with which a 
given transposon inserts into target DNA, the requirements for specific cis-acting elements 
required within the transposon itself (for example the size or properties of the flanking inverted 
repeats), the ability of the transposon to carry ‘cargo’ of sufficient size and with the desired 
properties, and ease of use.  We have found the Drosophila mariner element Mos1 to be 
satisfactory in these respects, and here we describe the basic elements of the transposon relevant 
to its application in vitro.   
1.1.  mariner and in vitro transposition reactions.  The Drosophila element Mos1 is a member 
of the mariner/Tc1 family, which occurs in most kingdoms of living organisms (18, 19).  
Typically mariner/Tc1 elements are small, encoding only the transposase and cis-acting elements 
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through a cut and paste mechanism (21), in which recognition of the inverted repeats (IR) by the 
transposase results in excision of the donor element.  This is subsequently inserted into a TA 
dinucleotide of the target molecule, and accompanied by duplication of the TA flanking the 
insertion site (22).  In vitro experiments have shown that the transposition reaction requires only 
transposase and transposon cis-elements, without the need for cellular factors (15, 17, 21, 23, 
24).  For Drosophila Mos1, the cis-acting elements required for transposition include the 28 bp 
5’ and 3’ inverted repeats, along with some internal nucleotides (no greater than 38 and 5 
additional internal nucleotides on the 5’ and 3’ sides, respectively; 17, 23).  While here we focus 
on in vitro applications, it is notable that the mariner system has been shown to function in vivo 
in a variety of different organisms including Leishmania, insects and vertebrates (25-29).  Most 
of the mariner transposon derivatives described below can be used in vivo as well, in any 
species. 
Our understanding of the mechanism of Mos1 transposition has lead to the development 
of a minimal, “empty” transposon donor, pELHY6∆-0 (Fig. 2), into which a variety of 
transposon ‘cargos’ have been inserted previously (23).  New cargos may be designed and 
rapidly introduced into this vector as desired by the experimenter.  A variety of transposons have 
been created previously, and potential applications such as insertional mutagenesis and gene 
trapping are summarized in Table 1.  A typical in vitro Mos1 transposition reaction consists of 
the donor plasmid (ex. /GEP3/, Fig. 2, Table 1), target DNA (a cLHYG-based cosmid for 
example; Fig. 2) and purified transposase.  The properties and requirements for these elements 
are discussed below. 
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bacterial/Leishmania selectable marker (HYG here) and origin of replication (OriR6K) (Fig. 2).  
For propagation in E. coli, the OriR6K origin requires the pir gene product, which is provided by 
the use of appropriate E. coli host strains when growing this plasmid (often harboring a λpir 
lysogen).  This allows one to select against the donor plasmid following transformation of the in 
vitro transposition reaction mix into pir- E. coli (this comprises virtually all common E. coli 
recipients).  In this particular donor plasmid, the presence of a Leishmania marker permits 
introduction into parasites by HYG selection and incorporation into in vivo transposition 
approaches.  Note that the signals for replication, transcription and/or mRNA processing differ 
considerably between E. coli and Leishmania; briefly, E. coli markers require promoters and 
plasmids require origins of replication for episomal maintenance.  In contrast, in Leishmania all 
that is required is a trans-splice acceptor site upstream of the marker ORF, as transcriptional and 
replication origin requirements are quite relaxed (30).  These differences must be taken into 
account when designing new transposons, and it can also be used to the researcher’s advantage in 
various ways.   
As a target plasmid, most common laboratory plasmid, cosmid and BAC vectors can be 
used; the specific requirements are that the target DNA should not contain an OriR6K for 
replication.  The target marker should not be the same as ones borne within the transposon or in 
its donor background (note that in the cLHYG example shown, the HYG gene lacks an E. coli 
promoter and thus does not confer resistance in bacteria).  Transposition efficiencies are highest 
if the target DNA is supercoiled and its “quality” is high (17).  
Mos1 transposase is purified and stored as described below.  Typically transposons 
require Mg
+2 for activity, however Mn
+2 can be used as this relaxes the requirement for insertion 
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overproduction inhibition (15), Mos1 shows simple saturation kinetics, and increasing 
transposase yields increasing transpositions until a plateau is reached (17). 
Following incubation, the in vitro transposition mix (which contains both donor and 
target plasmids as well as the desired transpositions) is transformed into pir- E. coli and plated 
on drugs which select for both the transposon (phleomycin in the example of /GEP3/ here) and 
the target (ampicillin here).  Transposition efficiencies can be calculated by comparing platings 
on ampicillin alone vs. ampicillin + phleomycin, and can approach 10
-3/target.  
The number of individual transpositions required depends upon the particular application.  
While mariner demands TA residues for insertion under standard conditions, these are 
sufficiently abundant even in the GC-rich Leishmania genome to provide plenty of potential 
target sites, and the requirement for TA can be relaxed if transposition is performed in the 
presence of Mn
+2 (17).  We have found that for cosmid targets, several hundred independent 
insertions are usually sufficient for sequencing and inactivation of most potential target genes.  
For the recovery of specific gene fusions, larger libraries may be required, since one has the 
additional constraints of inserting into TAs in the appropriate strand and reading frame.  For 
these purposes one thousand independent insertions into a cosmid target should suffice.  Note 
that with current in vitro transposition efficiencies and Leishmania transfection efficiencies (31) 
one may contemplate scoring libraries in excess of 10
5 independent insertions. 
1.2  The mariner toolkit.  Table 1 describes some of the mariner derivatives that have been 
developed and used successfully in our laboratory.  A variety of applications and transposons can 
be envisaged, and the ones below provide some perspective on the factors relevant to their design 
and utilization.  The transposons are described briefly below; many can be used for the recovery 
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regulatory elements (the GEP transposon series, for example).  All transposons can be used for 
primer-island sequencing, and insertional inactivation.  Most transposons contain autonomous 
bacterial selectable markers and can be used in the in vitro system, except for pELHY6TK-PG 
(thereby restricting it to in vivo applications).  Since Leishmania uses a polycistronic 
transcriptional mechanism to generate mRNAs and relies heavily on post-transcriptional 
regulatory mechanisms to control protein expression, we have given the most attention to 
transposons that facilitate the recovery of protein fusions.  
  Transposons /GEP3*, /GEP3/ and /GEP2/ contain a GFP-PHLEO fusion protein 
(Table 1); the linker peptide between the GFP and PHLEO additionally functions as an E. coli 
promoter, and in bacteria this cassette confers phleomycin resistance constitutively (as required 
for use in the in vitro system).  Importantly, the GFP lacks an initiating ATG codon, and thus in 
eukaryotes GFP-PHLEO expression can only be obtained following insertion of the /GEP 
transposons into an open reading frame expressed by the target DNA (Fig. 3).  Such insertions 
can be selected for by phleomycin resistance (only in eukaryotes), or screened for by GFP 
expression.  Note that phleomycin resistance can be affected by compartmentalization of the 
fusion protein; if the PHLEO protein domain is restricted to a compartment such as the 
glycosome which is segregated from the nucleus (the site of action of phleomycin), resistance 
will be abrogated (32).   
   /GEP3* differs from /GEP3/ and /GEP2/ in that it contains a stop codon following the 
GFP-PHLEO fusion protein.  Thus, the protein fusions recovered bear the N but not C terminus 
of the trapped protein (Fig. 4A,C).  In /GEP3/ and /GEP2/ the stop codon has been eliminated so 
that an intact reading frame is maintained across the entire transposon, enabling the recovering of 
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transposon is referred to as a ‘sandwich’ transposon (Fig. 4B,C).  Since mariner elements must 
insert into TAs which can occur in any reading frame, /GEP3/ differs from /GEP2/ in which 
frame can be trapped (due to the sequence of the 5’ mariner inverted repeats it is not possible to 
make a “/GEP1/” transposon for protein trapping; Fig. 3).  While all GEP transposons can be 
used to study translational regulation, the ability of sandwich transposon to retain both N and C 
terminal sequences which often contain important protein targeting information (for example, 
membrane anchoring domains; Fig. 4C) is important for some purposes. 
  Transposon /NEO*ELSAT (Table 1) creates a translational fusion to the NEO 
selectable marker.  It should be noted that the ability of the NEO protein to tolerate N-terminal 
fusions varies considerably amongst different protein targets, in contrast to GFP, PHLEO and β-
galactosidase which are more permissive.  An additional element in this transposon is the 
selectable marker SAT (streptothricin resistance), which contains both a Leishmania splice 
acceptor site and an E. coli promoter, allowing for selection for the transposon with SAT and 
protein fusions with NEO in Leishmania. 
Transposon GFP*K (Table 1) can used to generate GFP fusions in a manner similar to 
the /GEP transposons, as its GFP also lacks an ATG start codon.  Additionally, it bears a rare 
restriction endonuclease (I-PpoI) which is helpful in mapping transposon insertion sites in large 
targets or the genome in vivo.   
The transposon carried in pELHY6TK-PG (Table 1) contains a PHLEO-GUS 
translational fusion containing its own start codon.  This transposon lacks a constitutive bacterial 
selectable marker, and contains an E. coli oriC replication origin; thus it cannot be used in the in 
vitro system, and can only be used in vivo.  There, the oriC replication origin facilitates the 
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transposon donor is carried on pELHY6TK, which is a modified version of pELHY6∆-0; it 
additionally bears a conditionally negative selectable marker (herpesvirus Thymidine Kinase) 
active in Leishmania (33). 
Transposon /-2x5 (Table 1) was designed for transposon-mediated linker-insertional 
mutagenesis (TIMLI; 34).  It contains an E. coli kanamycin resistance marker, flanked by a 
“symmetric” mariner element in which the 5’ IR was duplicated.  Importantly, this IR contains 
two sites that occur relatively infrequently in Leishmania, SexAI and BsrGI (and most 
importantly should not occur in targets where they are to be used).  In TIMLI mutagenesis, one 
first generates a large library of transposition events into the target.  Then, this transposition pool 
is collected en mass, DNA prepared, digested with SexAI or BsrGI, diluted and self-ligated, and 
transformed back into E. coli.  This yields excision of the transposon, leaving behind only an 
insertion of 12 or 18 nucleotides (encoding 4 or 6 amino acids respectively).  Thus one can 
generate a library of short-peptide insertions for subsequent functional analysis, such as the 
mapping of protein domains and activities.   
In this chapter we will describe how to express and purify active Mos1 transposase, and 
carry out in vitro transposition reactions.  
 
2.  Materials 
2.1 Expression of Mos1 transposase 
1.  E. coli strain expressing T7 polymerase (BLR (DE3)) from Novagen. 
2.  Vector expressing His6-tagged Mos1 transposase (pET19-Tpase, Beverley lab strain 
B4289; 23) 
  103.  1 M IPTG (isopropyl-β-D-thio-galactopyranoside) stock solution 
4.  Resuspension buffer (20 mM Tris-HCl pH 7.6, 2 mM MgCl2, 25 % sucrose, 0.6 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM benzamidine (BZA) and 1 mM 
dithiothreitol (DTT) 
5.  Liquid nitrogen or Sonicator 
2.2 Purification of transposase 
1.  Lysis buffer (20 mM Tris-HCl pH 7.6, 4 mM EDTA, 200 mM NaCl, 1 % deoxycholate, 1 
% nonylphenoxy polyethoxy ethanol (NP-40), 0.6 mM PMSF, 1 mM BZA, 1 mM DTT) 
2.  DNAseI 
3.  MgCl2 
4.  Lysozyme  
5.  Buffer A (20 mM Tris-HCl pH 8, 500 mM NaCl, 6 M guanidine HCl, 1 % NP-40, 70 
mM imidazole) 
6.  Wash buffer (50 mM NaH2PO4, 300 mM NaCl, 100 mM imidazole, adjusted to pH 8.0 
using NaOH) 
7.  Elution buffer (50 mM NaH2PO4, 300 mM NaCl, 500 mM imidazole, adjusted to pH 8.0 
using NaOH) 
8.  Ni-NTA agarose (Qiagen, # 30210) 
9.  Purification column (Qiagen, # 34964) 
10. SDS-PAGE gel 
11. Dialysis slide (Slide-A-Lyzer® dialysis cassette, 10,000 MW cutoff ; Pierce catalog 
number 66425) 
  1112. Dialysis buffer A (10 % glycerol, 25 mM Tris-HCl pH 7.6, 50 mM NaCl, 5 mM MgCl2, 2 
mM DTT) 
13.  Dialysis buffer B (10 % glycerol, 25 mM Tris-HCl pH 7.6, 50 mM NaCl, 5 mM MgCl2, 
0.5 mM DTT) 
14. 100 % Glycerol 
2.3 In vitro transposition assay 
1.  Reaction buffer (25 mM HEPES pH 7.9, 1 mM DTT, 5 mM MgCl2, 100 mM NaCl2) 
2.  100 % Glycerol 
3.  Purified BSA (10 mg/ml) (New England Biolabs) 
4.  Stop buffer (50 mM Tris-HCl pH 7.6, 0.5 mg/ml proteinase K, 10 mM EDTA, 250 mg/ml 
yeast tRNA) 
5.  3 M NaAcetate 
6.  100 % ethanol 
7.  70 % ethanol 
8.  Bacterial electoporator 
9.  pir- E. coli electrocompetent cells like DH10B  
10. 25:24:1 Phenol/chloroform/isoamyl alcohol  
11. 10 mM Tris pH 7.5 
12. Ampicillin, hygromycin, nourseothricin (Dr.Walter Werner; WeBioAge@aol.com) and 
Zeocin (Invitrogen)  
13. Lb medium (with appropriate drug)/plates 
 
  123.  Methods 
3.1 Expression of Mos1 transposase 
1.  Transform BLR (DE3) with plasmid expressing Mos1 transposase; plate on ampicillin 
(100 µg/ml). 
2.  The following day, pick a number of colonies and resuspend into LB with ampicillin (100 
µg/ml) . 
3.  Use the above solution to inoculate 100 ml of media.  Incubate culture at 37°C to an 
OD600 of 0.6. 
4.  Induce expression of transposase by adding IPTG to a final concentration of 1 mM.  After 
5 hours of induction harvest cells by centrifugation at 1,303g for 10 min at 4°C. 
5.  Resuspend in 0.5 ml of resuspension buffer and flash freeze in liquid nitrogen and store at 
-80 c. (see Note 1) 
3.2 Purification of Mos1 transposase 
1.  Thaw cells at room temperature. 
2.  Add 1 mg/ml of lysozyme and incubate for 5 min at room temperature.  Next, add 1 ml of 
lysis buffer and incubate at room temperature for 15 minutes and then for 20 min after adding 60 
µg of DNAseI and MgCl2 to 10 mM.  
3.  All subsequent steps are conducted at 4°C. 
4.  Pellet inclusion bodies at 14,000g in a microcentrifuge and wash three times with 1 ml of 
100 mM Tris-HCL pH 7.6.  Resuspend inclusion bodies to a final volume of 4 ml in Buffer A.  
Add 1 ml of 50 % Ni-NTA agarose and gently shake solution for 1 hour. 
5.  Load mixture onto column (Qiagen) and collect flow-through. 
6.  Wash twice with 4 ml of Wash buffer and collect wash fractions. 
  137.  Elute four times with 0.5 ml of Elution buffer. 
8.  Run 20 µl of eluted protein on an SDS-PAGE gel.  On a 12 % SDS-PAGE gel the 
purified His-tagged Mos1 transposase runs at approximately 50 kDa (see Note 2).  Also load an 
aliquot of the non-induced culture, column flow-through and wash flow-through.   
9.  Pool the fractions containing the most transposase.  Place the transposase into dialysis 
slide, ensuring not to overfill.  Conduct dialysis in 1 liter of dialysis buffer A for 6 to 8 hours at 
4°C.  Replace dialysis buffer with 1 liter of dialysis buffer B and incubate overnight at 4°C. (see 
Note 3) 
10.  Centrifuge solution at 10,000g for 20 min at 4°C to remove precipitate. 
11.  Add glycerol to a final concentration of 50 %.  Store at -20°C.  
3.3 In vitro transposition 
1.  Set up a standard transposition reaction in a 0.6 ml microcentrifuge tube to a final volume 
of 20 µl.  
2 µl of 10x transposition buffer 
2 µl of 100 % glycerol (Warm glycerol at 65 C to ease pipetting) 
0.5 µl of BSA at 10 mg/ml 
1 µl of donor plasmid (32 fmol) 
6 µl of target plasmid (10 fmol, see Note 4) 
5 µl of transposase (100 nM, see Note 5) 
3.5 µl of sdH2O 
2.  Incubate reaction at 30 C for 1 hour to overnight.  
3.  Add 80 µl of stop buffer and incubate for 30 minutes at 37 °C 
  144.  Add 100 µl of 25:24:1 phenyl/chloroform/isoamyl alcohol and vortex.  Separate phases 
by centrifugation at 14,000g for 15 min.  Remove approximately 90 µl of the upper layer into a 1 
ml microcentrifuge tube.  Add 10 µl of 3 M NaAcetate and 250 µl of EtOH and incubate at -
80°C for at least 1 hour. 
5.  Precipitate DNA by centrifugation at 14,000g for 30 minutes at 4°C.  Wash precipitated 
DNA with 1 ml of 70 % EtOH and centrifuge at 14,000g for 15 minutes at 4°C.  Resuspend the 
pellet in 10 µl of 10 mM Tris pH 7.5. 
6.  Electroporate 2 µl of the purified transposition reaction into DH10B electrocompetent 
cells (see Note 6).  Add 1 ml of Lb media and incubate for 1 hour at 37°C.  Plate transfectants 
onto selective plates (see Note 7 and 8) and incubate at 37°C overnight. 
7.  Depending on the purposes, colonies may be picked individually or large pools made for 
DNA preparations and subsequent analysis en mass, for example following transfection into 
Leishmania or other organisms (see Note 9; 31). 
 
4.  NOTES 
1.  Alternatively, one can sonicate cells using a microtip at 40-50 % power for 20 bursts.  The 
cells must be kept on ice during sonication.  Afterwards one can proceed directly to step 3.2.2 
excluding the addition of lysozyme. 
2.  The predicted molecular weight of the His-tagged Mos1 transposase is 43.6 kDa.  The altered 
mobility of the transposase during electrophoresis may result from the presence of the basic 
histidine residues.  Antibodies to the poly-histidine residues specifically recognize the 50 kDa 
band by western blot hybridization. 
  153.   The recovery of active, properly folded Tpase is very sensitive to the refolding conditions.  
Previous work has demonstrated that rapid dilution at low pH or dialysis of detergent solubilized 
proteins results in no active enzyme (17).  Omission of the column purification step also results 
in no enzyme activity likely due to the presence of an unknown inhibitory factor.  However, 
rapid dilution at pH 8 or refolding on a column using a linear urea gradient (8-0 M urea) has 
been shown to yield Tpase activity (17, 24).  Thus, while the refolding protocol described in this 
article has worked effectively in this laboratory ultimately the optimal refolding conditions needs 
to be qualitatively determined by each investigator.   
4.  The quality of DNA is very important to transposition efficiencies.  The preparation of donor 
and recipient DNA containing a high proportion of supercoiled DNA results in high transposition 
efficiencies.  Qiagen midi preparations are generally suitable for this goal.  However, when 
preparing cosmid DNA one should take special care to avoid shearing the DNA.  Transposition 
efficiency reaches a maximum at around 150 ng of donor plasmid.  
5.  The concentration of transposase is determined by the micro-BCA method (Pierce).  
Concentration may also be determined by UV absorbance (ε280nm = 76, 989 M
-1cm
-1); note that 
these measurements lead to differences in estimation of transposase concentration by a factor of 
3 (17).  Different batches of purified transposase can have different transposition efficiencies.  
This difference probably arises from batches of Mos1 transposase containing different amounts 
of correctly folded transposase.  Therefore, each batch should be tested before conducting large 
scale transposition reactions.  The transposition efficiency reaches a plateau at around 100 nM of 
transposase and remains at this level at higher concentrations (17).   
6.  The use of high efficiency electrocompetent cells work best.  Invitrogen GeneHogs
® 
electrocompetant cells can yield 1 x 10
10 transformants per µg of pUC vector. 
  167.  Plate 10 µl of a 1/100 dilution of the transformation onto medium containing the appropriate 
antibiotic for the resistance marker found (ex. Ap, 100 µg/ml, Fig. 2) on the recipient plasmid.  
The number of Ap
R colonies multiplied by the dilution factor (in this case by 10000) is the 
transformation efficiency.  The remaining 990 µl of cells are plated onto medium containing 
antibiotics for the resistance markers found on the recipient plasmid and the transposon cassette 
(such as Ap and Phleo in the example shown in Fig, 2; 100 µg/ml and 50 µg/ml respectively).  
Transposition efficiency is determined by dividing the number of Ap
R,Phleo
R colonies by the 
transformation efficiency (obtained in previous step).  Control transposition efficiencies should 
range from 10
-4 to 10
-3. 
8.  One can also estimate the transposition efficiency of a vector like pELHY6TK-PG which 
contains no bacterial selectable marker.  To accomplish this, a negative selectable marker like the 
product of the ccdB (control of cell death) gene in placed in the bacterial plasmid, which 
additionally containing positive selectable marker (Kanamycin, Km
R).  Examples of this are the 
pZERO system available from Invitrogen.  Transformation of this plasmid into bacteria lacking 
the gyrase gene results in Km+ colonies.  However, cell death occurs when transfected into 
strains containing gyrase like TOP10.  An in vitro transposition reaction is performed with 
equimolar amounts of this plasmid (Km
R) and a standard plasmid target (Chloramphenicol, Cm
R) 
in a strain lacking gyrase.  The transposition reaction is subsequently transformed into TOP10 
bacteria.  One half of the transformation is plated onto chloramphenicol plates (30 µg/ml) and the 
other half is plated onto kanamycin plates (50 µg/ml).  The number of colonies obtained when 
plated on Kanamycin represents transposition events into the ccdB gene.  The ratio of Km
R / Cm
R 
represents the transposition efficiency of this transposon.  
  179.  If one is planning transfections into Leishmania it is critical to first determine the sensitivity 
of your specific strain under the exact circumstances you plan to use.  Drug sensitivities vary 
greatly amongst different strains and species, in different media, and interactions can occur if 
two drugs are used simultaneously.  First determine the EC50 in liquid media; then, carry out a 
‘mock’ transfection followed by inoculation or plating onto media containing drug 
concentrations ranging upwards from 3-4 of the liquid media EC50.  Since high drug 
concentrations inhibit the recovery of bona fide transfectants, the goal is to identify the minimal 
drug concentration that kills untransfected/drug sensitive cells.  In Leishmania drug 
concentrations typically are 15-30 µg/ml for G418/geneticin, 25-40 µg/ml for phleomycin, 15-30 
µg/ml for hygromycin B and 100 µg/ml for nourseothricin, but exceptions are common. 
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  18Table and Figure Legends. 
Table 1.  Examples of Mos1 transposons and their properties and applications.  All 
transposons listed can be used for insertional mutagenesis and sequencing.  Symbols are as 
described: AG, Leishmania splice acceptor; SAT, nourseothricin resistance marker; Km, 
kanamycin resistance marker, GFP, modified green fluorescent protein; PHLEO, 
phleomycin/zeocin resistance marker; “/”indicates a gene lacking a start or stop codon 
respectively; “*” indicates an in-frame stop codon; black arrows, E. coli promoter; open triangle, 
5’ inverted repeat; grey triangle, 3’ inverted repeat; oriC, oriC origin of replication; and BsrGI 
and SexAI, unique restrictions sites used in TIMLI mutagenesis.. 
 
Fig. 1.  Transposon mutagenesis strategies.  (A) Shuttle mutagenesis begins with in vitro 
transposition into target DNA (plasmid or cosmid) to create an insertion library.  The transposon 
library is then transfected into Leishmania, and recovered by selection on the drug resistance 
marker found on the transposon therein in various ways.  (B) In vivo mutagensis requires the 
establishment of an active transposition system in the parasite itself.  This could be accomplished 
in several ways; stable expression of transposase and stable introduction of the transposon has 
been successful (29).  Ideally, one would prefer transient introduction of the transposition 
system, for example using transient or regulated expression of transposase, and/or transient 
introduction of donor transposons.  Alternatively, one could form a transposase-transposon 
complex in vivo, and then introduce this for subsequent transposition in vitro.  This has not yet 
been demonstrated in the mariner system but it works well with transposon Tn5 in a variety of 
eukaryotes (35, 36).  Reprinted with permission from (37). 
 
  19Fig.  2.  Mos1 vectors and the in vitro transposase reaction.  Panel A:  The ‘empty’donor 
plasmid pELHY6∆-0 contains the minimal cis-element (open arrow heads) with the 5’ and 3’ IRs 
and some internal nucleotides (Fig. 3A).  The vector contains the E. coli OriR6K origin (striped 
box) for propagation in a λpir+ strain and a HYG selectable marker (internal black line); this 
particular marker contains a Leishmania splice acceptor site (AG) for expression in Leishmania 
and an E. coli promoter (black arrow).  For use one can insert a variety of ‘cargo’ within the 
inverted repeats, at the unique MslI, XbaI or SbfI sites (Fig. 3A).  In this figure the donor element 
is pELHY6∆-/GEP3/, created by insertion of the /GEP3/ (Table 1).  For simplicity only the E. 
coli PHLEO resistance marker is shown in /GEP3/.  Panel B:  The basic in vitro transposase 
reaction contains a donor element, target DNA and transposase (shaded area).  In this example, 
the transposon target is a cosmid DNA which contains an E. coli ampicillin resistance marker 
(Ap) and an OriC origin of replication (open box).  After in vitro transposition into a TA 
dinucleotide, the DNA is transformed into a λpir- strain (like DH10B) to select against the donor 
plasmid.  Bacterial transformants are plated on Ap/PHLEO to select for transposition.  Target 
DNAs containing transpositions can then be transfected into Leishmania, and fusion proteins 
identified by selecting or screening for PHLEO or GFP expression respectively.  
 
Fig. 3.  Nucleotide sequences of Mos1 cis-element and pELHY6∆-/GEP3/, pELHY6∆-
/GEP2/ chimeric genes.  (A) The minimal Mos1 element used in our work contains essential cis-
elements consisting of the 5’ and 3’ inverted repeats (shaded gray arrows) and the internal 38 and 
5 internal nucleotides (non-shaded capital letters).  The six potential Mos1 reading frames 
coming in from flanking DNAs across the IRs are shown with arrows (labeled 1-6) while start 
and stop codons in each frame is shown by M or X respectively.  Unique restriction sites found 
  20within the empty transposon suitable for the addition of ‘cargo’ are shown.  (B) Putative 
chimeric genes created by insertion of the /GEP3/ and GEP2/ transposons into target TA 
dinucleotides in the third or second reading frame respectively.  Reprinted with permission from 
(23). 
 
Fig. 4.  Diagram of potential translational fusions obtained with transposons /GEP3* and 
/GEP3/.  Both transposons yield translation fusions when inserted in frame into target ORFs, 
which express a GFP-PHLEO resistance fusion protein domain (Table 1).  Note that phleomycin 
resistance can be affected by compartmentalization of the fusion protein; if the PHLEO protein 
domain is restricted to a compartment such as the glycosome which is segregated from the 
nucleus (the site of action of phleomycin), resistance will be abrogated (32).  (A) The 
pELHY6∆-/GEP3* transposon encodes a bifunctional GFP-PHLEO protein with a stop codon 
after the PHLEO domain.  Thus fusion proteins contain only N-terminal sequence information 
from the target.  (B) The pELHY6∆-/GEP3/ transposon contains an ORF across the entire 
transposon (both IRs and the bifunctional GFP-PHLEO protein).  C) Comparison of the use of 
‘terminator’ vs ‘sandwich’ protein fusions.  In this example the properties of fusion proteins 
generated by /GEP3* and /GEP3/ are compared following in frame insertion into a typical 
membrane surface protein, which bears an N terminal signal peptide and C-terminal membrane 
anchor.  With /GEP3* the C-terminal segment is lost, resulting in secretion of the fusion protein 
from the cell, while with /GEP3/ retention of the C-terminal segment results in the formation of a 
surface membrane anchored fusion protein. 
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